Key features and details
- Expression system: Escherichia coli
- Purity: >= 95% SDS-PAGE
- Endotoxin level: <= 1.000 Eu/µg
- Active: Yes
- Suitable for: SDS-PAGE, Functional Studies
- High batch-to-batch consistency
- Optimal bioactivity
- Guaranteed identical to human native proteins
- >95% purity
- Ultra-low endotoxin levels: <0.005 Eu/µg
- Carrier and tag free
Product nameRecombinant mouse RANKL protein (Active)
See all RANKL proteins and peptides
ab129136 activity is measured by its ability to induce osteoclast formation on mouse RAW264.7 cells using a concentration of 5.0-10.0 ng/mL (or ≥ 2.0 x 10^4 units/mg).
Purity>= 95 % SDS-PAGE.
UV spectroscopy at 280 nm. Purified using standard chromatographical techniques.
Endotoxin level<=1.000 Eu/µg
Expression systemEscherichia coli
Protein lengthProtein fragment
SequenceMPAMMEGSWLD VAQRGKPEAQ PFAHLTINAA SIPSGSHKVT LSSWYHDRGW AKISNMTLSN GKLRVNQDGF YYLYANICFR HHETSGSVPT DYLQLMVYVV KTSIKIPSSH NLMKGGSTKN WSGNSEFHFY SINVGGFFKL RAGEEISIQV SNPSLLDPDQ DATYFGAFKV QDID
Predicted molecular weight20 kDa
Amino acids143 to 316
Our Abpromise guarantee covers the use of ab129136 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped at 4°C. Store at -20°C or -80°C. Avoid freeze / thaw cycle. For long term storage it is recommended to add a carrier protein on reconstitution (0.1% HSA or BSA).
Constituents: 0.16% Sodium phosphate, 0.29% Sodium chloride
Lyophilized from a sterile (0.2 micron) filtered aqueous solution.
This product is an active protein and may elicit a biological response in vivo, handle with caution.
ReconstitutionCentrifuge vial before opening. Gently pipet and wash down the sides of the vial to ensure full recovery of the protein into solution. It is recommended to reconstitute the lyophilized product with sterile water at a concentration of 0.1 mg/mL, which can be further diluted into other aqueous solutions. Allow several minutes for complete reconstitution.
FunctionCytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK. Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. May be an important regulator of interactions between T-cells and dendritic cells and may play a role in the regulation of the T-cell-dependent immune response. May also play an important role in enhanced bone-resorption in humoral hypercalcemia of malignancy.
Tissue specificityHighest in the peripheral lymph nodes, weak in spleen, peripheral blood Leukocytes, bone marrow, heart, placenta, skeletal muscle, stomach and thyroid.
Involvement in diseaseDefects in TNFSF11 are the cause of osteopetrosis autosomal recessive type 2 (OPTB2) [MIM:259710]; also known as osteoclast-poor osteopetrosis. Osteopetrosis is a rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. The disorder occurs in two forms: a severe autosomal recessive form occurring in utero, infancy, or childhood, and a benign autosomal dominant form occurring in adolescence or adulthood. Autosomal recessive osteopetrosis is usually associated with normal or elevated amount of non-functional osteoclasts. OPTB2 is characterized by paucity of osteoclasts, suggesting a molecular defect in osteoclast development.
Sequence similaritiesBelongs to the tumor necrosis factor family.
modificationsThe soluble form of isoform 1 derives from the membrane form by proteolytic processing (By similarity). The cleavage may be catalyzed by ADAM17.
Cellular localizationCytoplasm; Secreted and Cell membrane.
- Information by UniProt
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab129136 has been referenced in 3 publications.
- Liu X et al. Osteoclasts protect bone blood vessels against senescence through the angiogenin/plexin-B2 axis. Nat Commun 12:1832 (2021). PubMed: 33758201
- Lee SS et al. Comprehensive in vitro comparison of cellular and osteogenic response to alternative biomaterials for spinal implants. Mater Sci Eng C Mater Biol Appl 127:112251 (2021). PubMed: 34225890
- Elashiry M et al. Dendritic cell derived exosomes loaded with immunoregulatory cargo reprogram local immune responses and inhibit degenerative bone disease in vivo. J Extracell Vesicles 9:1795362 (2020). PubMed: 32944183